Click here for a PDF version of the program

Day 1, Thursday, May 12th
09:00-10:15 Antibody-drug Conjugates in Relapsed/Refractory Multiple Myeloma: from bench to bedside
Springer Healthcare IME symposium on-demand recording – Watch Now
10:15-10:35 Coffee Break
10:35-10:45 COMy 2022 kick-off: Welcome by Congress Co-Chairs
10:45-12:00 Session 1: How to assess disease risk
Chairs: Hervé Avet-Loiseau, France & Irene Ghobrial, USA
10:45-11:00 Diagnostic criteria and state of the art work-up
Shaji Kumar, USA
11:00-11:15 What is standard risk, high risk and ultra-high risk?
Hervé Avet-Loiseau, France
11:15-11:30 The role of the transcriptome
Jill Corre, France
11:30-11:45 The role of imaging
Elena Zamagni, Italy
11:45-12:00 Role of precursor conditions – no longer available on-demand
Irene Ghobrial, USA
12:00-12:30 Lunch Break
12:30-13:30 Taking center stage: is chromosome 1 the new headline in multiple myeloma?
Sanofi lunch symposium on-demand recording – Watch Now
13:30-13:40 Technical Break
13:40-15:00 Session 2: Mechanisms of resistance in myeloma
Moderators: Paola Neri, Canada & Niels van de Donk, The Netherlands
13:40-13:55 Resistance to IMIDs
Nizar Bahlis, Canada
13:55-14:10 Resistance to proteasome inhibitors
Marc Raab, Germany
14:10-14:25 Resistance to antibodies
Niels van de Donk, The Netherlands
14:25-14:40 Resistance to immune therapies – no longer available on-demand
Paola Neri, Canada
14:40-15:00 Roundtable discussion
All Speakers and Moderators
15:00-16:30 Session 3: Frontline therapy of transplant-eligible patients
Moderators: Nizar Bahlis, Canada & Philippe Moreau, France
15:00-15:15 Overview of induction regimens
Philippe Moreau, France
15:15-15:30 Role of consolidation (including double auto-transplant)
Michele Cavo, Italy
15:30-15:45 Special approaches in high-risk cytogenetics
Pieter Sonneveld, The Netherlands
15:45-16:30 Roundtable discussion
All Speakers and Moderators
16:30-17:00 Coffee Break
17:00-18:30 It’s MMy Life: Your specialty, my world
Industry-supported symposium
18:30-18:45 Technical Break
18:45-19:45 Session 4: Plenary lectures
Chair: Thierry Facon, France
18:45-19:05 Advances in Waldenstrom macroglobulinemia
Steven Treon, USA
19:05-19:25 iStopMM study – the impact of nationwide screening – no longer available on-demand
Sigurdur Kristinsson, Iceland
19:25-19:45 Q & A
Day 2, Friday, May 13th
08:00-08:30 Good morning coffee
08:30-09:00 Artificial Intelligence for precision medicine in Multiple Myeloma
OWKIN plenary presentation on-demand recording – Watch Now
09:00-09:15 Technical Break
09:15-10:15 Session 5: The IFM session
Chair: Philippe Moreau, France
09:15-09:35 The IFM strategy for non-transplant eligible patients
Salomon Manier, France
09:35-09:55 The IFM strategy for transplant eligible patients – no longer available on-demand
Cyrille Touzeau, France
09:55-10:15 MRD and clonal evolution: the latest IFM data
Jill Corre, France
10:15-11:15 Session 6: Updates from the recent frontline clinical trials
Chairs: Francesca Gay, Italy & Cyrille Tourzeau, France
10:15-10:30 OPTIMUM/MUK9 – no longer available on-demand
Martin Kaiser, UK
10:30-10:45 CONCEPT
Katja Weisel, Germany
10:45-11:00 FORTE
Francesca Gay, Italy
11:00-11:15 MASTER
Luciano Costa, USA
11:15-12:30 Session 7: Treatment of non-transplant eligible patients
Moderators: Thierry Facon, France & Kwee Yong, UK
11:15-11:30 Frailty assessment
Alessandra Larocca, Italy
11:30-11:45 Standard of care therapy
Thierry Facon, France
11:45-12:00 The patient perspective
Kwee Yong, UK
12:00-12:30 Roundtable discussion
All Speakers and Moderators
12:30-13:00 Lunch Break
13:00-14:15 Elevating standard of care in MM: unlocking the potential of novel BCMA combinations
GSK lunch symposium on-demand recording – Watch Now
14:15-14:25 Technical Break
14:25-16:10 Session 8: Management of special clinical situations
Moderators: Michel Delforge, Belgium & Graham Jackson, UK
14:25-14:40 COVID-19 vaccination in myeloma: where do we stand?
Heinz Ludwig, Austria
14:40-14:55 Practical considerations when using anti-CD38 antibodies
Torben Plesner, Denmark
14:55-15:10 Management of renal impairment
Joan Blade, Spain
15:10-15:25 Infection prophylaxis
Graham Jackson, UK
15:25-15:40 Cardiac complications
Michel Delforge, Belgium
15:40-15:55 Guidelines for the use of bisphosphonates
Evangelos Terpos, Greece
15:55-16:10 Roundtable discussion
All Speakers and Moderators
16:10-16:30 Coffee Break
16:30-18:00 Clinical utility of MRD for MM patients
Adaptive symposium on-demand recording – Watch Now
18:00-18:10 Technical Break
18:10-19:15 Session 9: Plenary lectures
Chair: Jean-Luc Harousseau, France
18:10-18:35 MRD evaluation: How, When and for which goal? – no longer available on-demand
Jesús San Miguel, Spain
18:35-19:00 Genomics of myeloma: what’s new?
Nikhil Munshi, USA
19:00-19:15 Q & A
19:15-19:30 Awards Ceremony: Presented by Congress Co-Chairs
Day 3, Saturday, May 14th
08:00-08:30 Good morning coffee
08:30-09:00 Innovation for Patients with Relapsed/Refractory Multiple Myeloma: Development of TALEN gene-edited Allogeneic CAR-T Therapies Targeting CS1
Cellectis plenary presentation on-demand recording – Watch Now
09:00-09:10 Technical Break
09:10-10:00 Session 10: The IMS session: Global view of state-of-the-art in myeloma – What are our strategies?
Chairs: Mohamad Mohty, France; Philippe Moreau, France & Nikhil Munshi, USA
09:10-09:15 Introduction
Nikhil Munshi, USA
09:15-09:25 Strategies for US Co-operative trials
Saad Usmani, USA
09:25-09:35 Strategies for European trials – no longer available on-demand
Cyrille Touzeau, France
09:35-09:45 Strategies for Asia-Pacific and Latin American
Andrew Spencer, Australia
09:45-10:00 What IMS can do for all
Philippe Moreau, France
10:00-10:50 Session 11: Hot debates
Chair: Mohamad Mohty, France
10:00-10:25 MRD to drive therapy
Pro
Bruno Paiva, Spain
Con
Meral Beksac, Turkey
Discussion
10:25-10:50 Immune therapies replacing ASCT frontline
Pro
Paul Richardson, USA
Con
Arnon Nagler, Israel
Discussion
10:50-11:20 Coffee Break
11:20-12:20 Session 12: Novel agents for relapse: the latest data about …
Chairs: Meral Beksac, Turkey & Enrique Ocio, Spain
11:20-11:30 Antibodies and IMIDs combinations for first relapse – no longer available on-demand
Xavier Leleu, France
11:30-11:40 Manipulation of apoptotic pathways – no longer available on-demand
Cyrille Touzeau, France
11:40-11:50 XPO inhibitors
Nizar Bahlis, Canada
11:50-12:00 CelMods
Sagar Lonial, USA
12:00-12:10 HDAC inhibitors
Enrique Ocio, Spain
12:10-12:20 Antibody-drug conjugates
Suzanne Trudel, Canada
12:20-13:00 Lunch Break
13:00-14:00 Giving new hope to patients with Multiple Myeloma: How?
14:00-14:10 Technical Break
14:10-15:45 Session 13: Immune therapy in relapsed/refractory myeloma
Moderators: Hermann Einsele, Germany & Sagar Lonial, USA
14:10-14:25 CAR T cells
Noopur Raje, USA
14:25-14:40 Bi-specific antibodies
Ajai Chari, USA
14:40-14:55 Management of CRS and neurotoxicity
Salomon Manier, France
14:55-15:10 Integrating immune therapies and autologous transplantation
Hermann Einsele, Germany
15:10-15:25 Immune therapies at first relapse: pro and con
Paul Richardson, USA
15:25-15:45 Roundtable discussion
All Speakers and Moderators
15:45-16:15 Coffee Break
16:15-17:25 Session 14: Plenary lectures
Moderators: Mohamad Mohty, France & Arnon Nagler, Israel
16:15-16:35 The requirements for operational cure
Jean-Luc Harousseau, France
16:35-17:05 Multiple myeloma cured in 2030: what are the next steps?
Kenneth Anderson, USA
17:05-17:25 Roundtable discussion
All Speakers and Moderators
17:25-17:30 In-Person Meeting Conclusions and Adjournment: Congress Co-Chairs
Day 4, Sunday, May 15thVIRTUAL ONLY
09:00-10:50 Session 15: Abstract communications
Chairs: Mohamad Mohty, France; Thierry Facon, France & Arnon Nagler, Israel
09:00-09:10 AN ONGOING PHASE I STUDY SHOWS CLINICALLY MEANINGFUL ACTIVITY AND MANAGEABLE SAFETY OF CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH HEAVILY PRE-TREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) [ENCORE]
Thierry Facon, France
09:10-09:20 EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CYTOKINE RELEASE SYNDROME WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
James Hoffman, USA
09:20-09:30 INSURE: A GLOBAL POOLED ANALYSIS (INSIGHT MM, UVEA-IXA, AND REMIX) OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) IN ROUTINE CLINICAL PRACTICE
Xavier Leleu, France
09:30-09:40

Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)

Philippe Moreau, France

09:40-09:50 DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN (BELAMAF) PLUS STANDARD OF CARE (SOC) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TI-NDMM)no longer available on-demand
Saad Usmani, USA
09:50-10:00 CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 COHORT B
Niels van de Donk, The Netherlands
10:00-10:10 UPDATE FROM A FIRST-IN-HUMAN PHASE 1 STUDY OF MODAKAFUSP ALFA (TAK-573), A FIRST-IN-CLASS IMMUNOCYTOKINE, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Dan T. Vogl, USA
10:10-10:20 CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) VERSUS PHYSICIAN’S CHOICE OF TREATMENT (PCT): A META-ANALYSIS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Katja Weisel, Germany
10:20-10:50 Q & A
10:50-11:00 Break
11:00-12:55 Session 16: Special lectures
Chairs: Mohamad Mohty, France; Thierry Facon, France & Arnon Nagler, Israel
11:00-11:20 MGUS: diagnosis, risk stratification and management
Vincent Rajkumar, USA
11:20-11:35 Treatment of the ultra-frail patients
Sonja Zweegman, The Netherlands
11:35-11:50 Maintenance approaches post-transplant
María-Victoria Mateos, Spain
11:50-12:00 Antibodies and proteasome inhibitors combinations for first relapse
Saad Usmani, USA
12:00-12:20 Therapy at first relapse: current data and perspectives
Meletios Dimopoulos, Greece
12:20-12:35 Defining disease aggressiveness during therapy
Gareth Morgan, USA
12:35-12:55 Advances in AL amyloidosis
Giampaolo Merlini, Italy
12:55-13:15 COMy 2022 Meeting Conclusions: Final roundtable virtual discussion
With:
Jill Corre, France
Luciano Costa, USA
Thierry Facon, France
Francesca Gay, Italy
Jean-Luc Harousseau, France
Giampaolo Merlini, Italy
Mohamad Mohty, France
Arnon Nagler, Israel
Vincent Rajkumar, USA